NCT06598007View on ClinicalTrials.gov

A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

June 20, 2027

Study Completion Date

June 30, 2027

Conditions
Solid Tumor, AdultColorectal CancerPancreatic Ductal Adenocarcinoma
Interventions
DRUG

CT3001

CT3001 is an Oral Solution, with active pharmaceutical agent, a small molecule inhibitor of GPR35, formulated with PEG 400, strawberry flavor, and anhydrous ethanol.

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Crossignal Therapeutics, Inc.

INDUSTRY